Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968990 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1RECQLPARP1HRH3 | |
| SCHEMBL968695 | 0.81 | PARP1 (0.47) | MCHR1KDM4EALDH1A1PARP1PRMT5 | |
| SCHEMBL967453 | 0.80 | HRH3 (0.39) | MCHR1KDM4EALDH1A1PARP1HRH3 | |
| SCHEMBL1018360 | 0.80 | KDM4E (0.46) | KDM4EALDH1A1RECQLPARP1HRH3 | |
| SCHEMBL13985864 | 0.78 | HRH3 (0.38) | KDM4EALDH1A1PARP1HRH3PRMT5 | |
| SCHEMBL967951 | 0.77 | PARP1 (0.52) | KDM4EALDH1A1PARP1PRMT5WDR77 | |
| SCHEMBL969343 | 0.76 | PARP1 (0.42) | KDM4EALDH1A1RECQLPARP1HRH3 | |
| SCHEMBL1020740 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1RECQLPARP1HRH3 | |
| SCHEMBL1020109 | 0.74 | KDM4E (0.41) | KDM4EALDH1A1RECQLPARP1HRH3 | |
| SCHEMBL971043 | 0.74 | PARP1 (0.43) | KDM4EALDH1A1RECQLPARP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | HRH3, HRH4, HRH1 | MCHR1 302/4885KDM4E 3037/4885ALDH1A1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.